While many potential inhibitors of ADAMTS-13 activity have been proposed (e.g., autoantibodies [28], plasma IL-6 [29], human neutrophil peptides [30], thrombospondin-1 [31], cell-free plasma Hb, platelet factor 4 (PF4) [10]), none of them has been tested in ESRD, highlighting a significant knowledge gap in the field of hemostasis in uremia. The gene discussed is IL6; the disease is uremia.